Novo Nordisk slides further on US competition, new CEO concerns

Novo Nordisk shares continued their steep decline, falling an additional 4.1% on Wednesday after Tuesday's 23% plunge that erased $70 billion, following a significantly lowered 2025 sales growth outlook and the appointment of a new CEO, Maziar Mike Doustdar. The revised guidance reflects intensified competition from "compounded" copycat versions of Wegovy in the U.S., a factor analysts suggest is still underestimated by management. Investors and analysts are expressing significant credibility concerns over the company's handling of the competitive landscape and the new CEO's initial lack of a clear strategic shift, prompting multiple downgrades.

Analysis

Novo Nordisk is facing a severe crisis of investor confidence, evidenced by a two-day share price collapse that erased $70 billion in market value, including a 23% drop on Tuesday and a further 4.1% on Wednesday. The catalyst was a significant reduction in the 2025 sales growth outlook, which the company attributed to persistent competition from 'compounded' copycat versions of its key weight-loss drug, Wegovy, in the United States. This development, which surprised investors, is viewed as a structural threat, as analyst commentary from Guggenheim highlights that Novo's new guidance does not assume a reduction in this competition. The situation is exacerbated by a perceived disconnect between management and the market, described by a Barclays analyst as a 'severe credibility issue.' The incoming CEO Maziar Mike Doustdar's initial comments about 'fantastic growth' and a focus on 'commercial execution' without a new strategic direction have failed to assuage concerns. This has prompted significant institutional reappraisal of the stock, reflected in downgrades from Barclays to 'equal-weight' and Bank of America to 'neutral.'

Key Decisions for Investors

• Given the slashed 2025 guidance and the unresolved threat from compounded drugs, investors should recognize that the stock's risk profile has fundamentally increased, warranting a reassessment of position sizing.
• It is critical to monitor for a clear strategic plan from the new CEO that directly addresses how Novo will combat U.S. copycat competition, as vague promises of improved 'commercial execution' are insufficient to restore market confidence.
• Despite the stock being down two-thirds from its peak, the fundamental outlook has deteriorated, so investors should exercise extreme caution before considering new long positions until there is tangible evidence of market share stabilization in the U.S. and a restored sense of credibility from management.